Overview
ECMO is widely used in patients with refractory respiratory and/or circulatory failure.The data shows that the incidence of bleeding and thrombotic events is still above 40%,and it is closely related to the increase in mortality rate.Therefore, optimizing ECMO anticoagulation management to reduce bleeding and thrombotic events is a key scientific issue that urgently needs to be addressed.
Eligibility
Inclusion Criteria:
- age older than 18 years old
- received ECMO because of severe respiratory failure
Exclusion Criteria:
- anticoagulant contraindications
- cerebral infarction or suspected patients
- severe hypertension
- women in gestational and lactational period
- hemophilia
- allergic to heparin or Nafamostat
- unwilling or unable to complete the study